Xencor, Inc. (XNCR) EPS Estimated At $-0.51 as of May, 8

April 17, 2018 - By Richard Doty

During Q4 2017 the big money sentiment increased to 1.21. That’s change of 0.31, from 2017Q3’s 0.9. 15 investors sold all, 28 reduced holdings as Xencor, Inc. ratio increased. 37 grew stakes while 15 funds amassed stakes. Funds hold 36.52 million shares thus 1.10% more from 2017Q3’s 36.12 million shares.
Moreover, Birchview Ltd Partnership has 0.16% invested in Xencor, Inc. (NASDAQ:XNCR). Teacher Retirement Systems Of Texas stated it has 0% in Xencor, Inc. (NASDAQ:XNCR). Landscape Mgmt Ltd Liability Corporation holds 0.02% of its capital in Xencor, Inc. (NASDAQ:XNCR) for 10,041 shs. Rhenman & Asset Ab holds 317,500 shs or 0.94% of its capital. Moreover, Dimensional Fund Advisors Limited Partnership has 0% invested in Xencor, Inc. (NASDAQ:XNCR). Ameritas Inv holds 0% or 3,040 shs. Sio Management Ltd Liability Com owns 1.36% invested in Xencor, Inc. (NASDAQ:XNCR) for 109,981 shs. Ecor1 Capital Lc has invested 0.28% in Xencor, Inc. (NASDAQ:XNCR). Jpmorgan Chase owns 283,641 shs. 33,563 are owned by Atlantic Group Limited Liability Company. Baker Bros Advsrs Limited Partnership has invested 0.17% in Xencor, Inc. (NASDAQ:XNCR). State Of Wisconsin Inv Board reported 29,000 shs. Lord Abbett And Ltd Limited Liability Company, New Jersey-based fund reported 252,611 shs. Artal Grp Incorporated Sa invested in 100,000 shs. Bank Of America Corporation De reported 12,524 shs or 0% of all its holdings.

Xencor, Inc. had 6 selling transactions and 2 buys since October 25, 2017. This’s net activity of $146,630. On Tuesday, February 27 $592,848 worth of Xencor, Inc. (NASDAQ:XNCR) was sold by Baracchini Edgardo Jr. The insider Foster Paul A sold 5,000 shs worth $125,050.

Investors expect Xencor, Inc. (NASDAQ:XNCR)’s quarterly earnings on May, 8., according to Faxor. Analysts expect change of 64.52 % or $0.20 from previous year’s $-0.31 EPS compared to current’s $-0.51 EPS. Wall Street now sees 104.00 % negative EPS growth despite Xencor, Inc. last quarter’s EPS of $-0.25. XNCR reached $30.05 on during the last trading session after $0.05 change.Xencor, Inc. has volume of 239,970 shares. Since April 17, 2017 XNCR has risen 17.37% and is uptrending. XNCR outperformed by 5.82% the S&P 500.

Xencor, Inc. (NASDAQ:XNCR) Ratings Coverage

Total analysts of 6 have positions in Xencor Inc (NASDAQ:XNCR) as follows: 5 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 83%. Since November 12, 2017 according to StockzIntelligence Inc Xencor Inc has 12 analyst reports. On Tuesday, November 28 the rating was initiated by Cantor Fitzgerald with “Buy”. On Monday, March 19 the rating was maintained by Wedbush with “Outperform”. On Wednesday, February 28 the rating was maintained by Piper Jaffray with “Buy”. On Thursday, March 29 Cantor Fitzgerald maintained Xencor, Inc. (NASDAQ:XNCR) with “Buy” rating. On Sunday, November 12 the rating was maintained by Piper Jaffray with “Buy”. The company rating was maintained by Piper Jaffray on Thursday, March 15. On Wednesday, March 28 Leerink Swann initiated Xencor, Inc. (NASDAQ:XNCR) rating. Leerink Swann has “Buy” rating and $3600 target. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, February 28. In Thursday, February 22 report Cantor Fitzgerald initiated the stock with “Buy” rating. On Monday, March 26 the stock of Xencor, Inc. (NASDAQ:XNCR) earned “Buy” rating by Piper Jaffray.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs.The firm is valued at $1.63 billion. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.Last it reported negative earnings. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies.

Xencor, Inc. (NASDAQ:XNCR) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.